Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
- Capsule
- Softgel Capsule
- Gummies
- Drop & drinks
- Tablets
- Effervescent Tablet
- Gel
- Powder
- Chewing Gum
- Pet Supplement
Veterinary raw materials
Phone: 86-18729212220
E-mail: sales@nutrition-oem.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Pharmaceutical intermediates Atazanavir Raw Materials Powder


Product Overview:
Azanavir is a new type of HIV-1 protease inhibitor developed by Bristol-Myers Squibb. Azanavir sulfate was released in the United States on June 20, 2003 and in Europe on March 2, 2004 under the trade name Reyataz.
Product Attributes
CAS:198904-31-3
MF:C38H52N6O7
MW:704.86
EINECS:812-543-8
Specification: 99% min Atazanavir Powder
Sample:Atazanavir
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Product Details
Atazanavir Powder Usage and Synthesis.
Azanavir is an inhibitor of azeptide HIV-1 protease. The product selectively inhibits the specific processing of viral Gag and GAG-pol polymers in HIV-1-infected cells, thereby blocking the formation of mature viruses. In vitro antiviral activity: The mean 50% inhibitory concentration (IC50) of azanavir against a large number of laboratory and clinical isolates of HIV-1 virus isolated from peripheral blood mononuclear cells, macrophages, CIM-SS cells, and MT2 cells without human serum was 2-5 nm.
Pharmacological action of Atazanavir.
This product is a novel azopeptidase protease inhibitor (PI). Its activity in vitro is not the same as that of non-peptide PIs such as Nelfinavir. This product is designed according to the X-ray diffraction study of enzym-azopeptidase complex and has a C-2 symmetric chemical structure. It is a highly selective and efficient inhibitor of HIV-1 protease, which inhibits the production of viral structural proteins, reverse transcriptase, integrase and protease by blocking the cleavage of viral gap and GAP-POL precursor polymerase, so that HIV-1-infected cells release non-infectious immature viral particles. This product has stronger inhibitory activity against multiple strains of HIV-1 virus than other PIs, and the median effective concentration (EC50) in vitro medium is 2.6 ~ 5.3nmol/L, and the 90% effective concentration (EC90) is 9 ~ 15nmol/L.

In vitro study of Atazanavir.
Atazanavir has effective activity against wild-type viruses in vitro with EC50 and EC90 of 2-5nM and 9-15nM, respectively. Atazanavir can effectively induce endoplasmic reticulum stress response in glioma cells, and the levels of GRP78 and CHOP are increased, and caspase-4 is activated, leading to cell death.
Product method of Bulk Atazanavir Powder.
Inquire This Product















